Alexander Fudukidis - Affimed NV Head Relations
| AFMD Stock | USD 3.00 0.38 14.50% |
Insider
Alexander Fudukidis is Head Relations of Affimed NV
| Address | Gottlieb-Daimler-Straße 2, Mannheim, Germany, 68165 |
| Phone | 49 621 560030 |
| Web | https://www.affimed.com |
Affimed NV Management Efficiency
The company has return on total asset (ROA) of (0.4931) % which means that it has lost $0.4931 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2408) %, meaning that it created substantial loss on money invested by shareholders. Affimed NV's management efficiency ratios could be used to measure how well Affimed NV manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -1.15. The current year's Return On Capital Employed is expected to grow to -1.42. At present, Affimed NV's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 162.2 M, whereas Intangible Assets are forecasted to decline to about 23.8 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Julie DeSander | Agenus Inc | N/A | |
| Stephen Evansfreke | ADC Therapeutics SA | 68 | |
| Lauren MD | PDS Biotechnology Corp | 64 | |
| Regina Grebla | Agenus Inc | N/A | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Craig Winter | Agenus Inc | N/A | |
| Bertrand Esq | Adaptimmune Therapeutics Plc | 57 | |
| Fiona Bor | Mereo BioPharma Group | N/A | |
| Christine CPA | Mereo BioPharma Group | 43 | |
| David Dornan | Elevation Oncology | 46 | |
| Hitto Kaufmann | Pieris Pharmaceuticals | 53 | |
| ACA BA | Adaptimmune Therapeutics Plc | 54 | |
| MS MBA | ADC Therapeutics SA | 51 | |
| Janetta Trochimiuk | PDS Biotechnology Corp | 61 | |
| Gordon MD | Pieris Pharmaceuticals | N/A | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Jackie Parkin | Mereo BioPharma Group | 66 | |
| Todd MD | Hepion Pharmaceuticals | 55 | |
| Valerie MD | Elevation Oncology | 46 | |
| Demetrios MD | Inozyme Pharma | N/A | |
| Mary DiBiase | X4 Pharmaceuticals | 63 | |
Management Performance
| Return On Equity | -1.24 | ||||
| Return On Asset | -0.49 |
Affimed NV Leadership Team
Elected by the shareholders, the Affimed NV's board of directors comprises two types of representatives: Affimed NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Affimed. The board's role is to monitor Affimed NV's management team and ensure that shareholders' interests are well served. Affimed NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Affimed NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Uwe Reusch, Head Culture | ||
| Denise Mueller, Chief Board | ||
| RPh PharmD, Chief Officer | ||
| Arndt MD, Chief Board | ||
| Angus Smith, CFO Board | ||
| Michael Wolf, Head Administration | ||
| Andreas MD, Chief Board | ||
| Mary Sandin, Vice Communications | ||
| Wolfgang Fischer, COO, Member of the Management Board | ||
| Pr Little, Founder Consultant | ||
| Adi Hoess, CEO, Member of the Management Board | ||
| Alexander Fudukidis, Head Relations |
Affimed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Affimed NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.24 | ||||
| Return On Asset | -0.49 | ||||
| Operating Margin | (74.06) % | ||||
| Current Valuation | 36.55 M | ||||
| Shares Outstanding | 16.39 M | ||||
| Shares Owned By Insiders | 6.00 % | ||||
| Shares Owned By Institutions | 36.98 % | ||||
| Number Of Shares Shorted | 982.93 K | ||||
| Price To Earning | (2.04) X | ||||
| Price To Book | 2.73 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Affimed NV is a strong investment it is important to analyze Affimed NV's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Affimed NV's future performance. For an informed investment choice regarding Affimed Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Affimed NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Affimed Stock refer to our How to Trade Affimed Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Affimed NV. If investors know Affimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Affimed NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.77) | Revenue Per Share 0.493 | Quarterly Revenue Growth (0.90) | Return On Assets (0.49) | Return On Equity (1.24) |
The market value of Affimed NV is measured differently than its book value, which is the value of Affimed that is recorded on the company's balance sheet. Investors also form their own opinion of Affimed NV's value that differs from its market value or its book value, called intrinsic value, which is Affimed NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Affimed NV's market value can be influenced by many factors that don't directly affect Affimed NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Affimed NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Affimed NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Affimed NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.